It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.Investing consistently during all types of market environments is key. So is maintaining your positions in quality companies unless and until your investment thesis regarding them no longer applies, or you feel that they have exhausted their value proposition for your portfolio.If you're looking for unstoppable grow ...

DexCom (DXCM) , a leader in glucose biosensing systems, has announced a strategic partnership with OURA, the developer of a leading smart ring technology. The collaboration is aimed at revolutionizing metabolic health management by integrating DexCom's glucose biosensor data with the biometric insights provided by the Oura Ring. The partnership will enable two-way data flow between DexCom glucose biosensors and apps and Oura Ring and the Oura App, and co-marketing efforts will help OURA and Dexcom reach mil ...

This medical device company is down but not out.Is the sky falling for DexCom (DXCM 0.89%)? Shares of the medical device specialist dropped off a cliff following its second-quarter earnings report. Unfortunately, the diabetes-focused company failed to impress investors yet again with its most recent quarterly update.At about $69 per share, DexCom's stock isn't that far off its 52-week low of $62.34 and is miles away from its 52-week high of $142. However, there remain good reasons to invest in the company.D ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Score ...

Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth. The stock of highly specialized healthcare company DexCom (DXCM -1.88%) wasn't the picture of health on Friday. It lost nearly 2% of its value in that day's trading session, on the back of an earnings release that raised investor concerns about slowing sales growth. The S&P 500 index outperformed the stock, and that's not saying much, as it essentially ended the day flat over Thursd ...

DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver w ...

DexCom, Inc. (DXCM) reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus Estimate of 43 cents by 4.7%. The company had reported earnings of 50 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 34 cents, up from the year-ago quarter's figure of 29 cents. Revenue Details of Dexcom Total revenues grew 2% (3% on an organic basis) to $994.2 billion year over year, beating the Zacks Consensus Estimate by 0.3%. The revenue g ...

My last article about DexCom, Inc. (NASDAQ: DXCM ) was published almost one and a half years ago and similar to my previous articles about Dexcom, I was bearish about the stock. And while there might be stocks, I am rather bearish about, IMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market ca ...

Financial Data and Key Metrics Changes - For Q3 2024, the company reported worldwide revenue of $994 million, a 2% increase compared to $975 million in Q3 2023, and a 3% organic growth [16] - US revenue was $702 million, down 2% from $714 million in Q3 2023, attributed to slower new customer starts and a decline in revenue per customer due to shifting channel dynamics [17] - International revenue grew 12% to $292 million, with organic growth at 16%, driven by stronger performance in core international markets [18] - Gross profit was $625.9 million, representing 63% of revenue, compared to 64.7% in Q3 2023 [19] - Operating income was $212 million, or 21.3% of revenue, down from $238.9 million, or 24.5% of revenue in Q3 2023 [20] - Net income for Q3 was $179.9 million, or $0.45 per share [20] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer starts in Q3, with a prescriber base expansion of nearly 35,000 clinicians since the sales force expansion in April [9] - The DME channel saw some incremental share loss, but trends stabilized late in the quarter as the team aligned better with partners [18] - The launch of the G7 system in Australia and the DexCom ONE+ system in 19 countries contributed to international growth [11] Market Data and Key Metrics Changes - The US CGM market growth slowed to about 10% in Q3, down from over 20% in the first half of the year, raising concerns about market dynamics [26] - Japan returned to growth with the new sales organization gaining momentum, achieving the highest new customer start month since entering the market in 2019 [12] Company Strategy and Development Direction - The company is focused on expanding its sales force and improving commercial execution to drive growth [7] - The launch of Stelo is seen as a pivotal moment in diabetes care, providing access to a broader audience and enhancing the care model for patients [13] - The company aims to stabilize and grow its DME channel by fostering better relationships and increasing prescription referrals [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to higher growth and continued margin expansion, with expectations of improved sales force productivity [7] - The company is maintaining its 2024 revenue guidance of $4.00 billion to $4.05 billion, reflecting organic growth of 11% to 13% [21] - Management acknowledged the challenges faced in Q3 but emphasized the positive momentum heading into Q4 and 2025 [24] Other Important Information - The company submitted its DexCom G7 15-day CGM system to the FDA for review, which is a top priority for future growth [15] - The company closed the quarter with approximately $2.5 billion in cash and cash equivalents, providing financial flexibility [20] Q&A Session Summary Question: Insights on US market performance and DME share - Management acknowledged a rocky quarter but noted strong new patient additions and stabilization in DME share towards the end of Q3, indicating positive momentum moving forward [24] Question: Concerns about CGM market growth - Management remains bullish on the CGM market, believing it can grow faster than the current 10% rate, despite recent challenges [27] Question: Progress on new patient starts and long-range plan - Management confirmed that they are on track with their long-range plan, expecting continued improvement in new patient starts and sales force productivity [28] Question: Clarification on record new starts - Record new patient starts did not include Stelo, focusing solely on the G-Series/T-Series insulin product base [30] Question: DME channel stabilization efforts - Management detailed efforts to improve relationships with DME partners and emphasized the importance of increasing patient referrals through this channel [35] Question: Timing and financial impact of FDA approval for the 15-day G7 - Management refrained from speculating on approval timing but expressed optimism about the potential financial impact once launched [38] Question: Pricing strategy for Stelo with DME partners - Management indicated that pricing for Stelo through DME partners would account for their margins while maintaining low costs for the company [42] Question: Competition in the Type 1 pump integrated segment - Management highlighted the strong reputation of DexCom sensors and their ongoing collaboration with pump partners to maintain market share [44] Question: 2025 outlook and growth expectations - Management reiterated confidence in achieving the $4.6 billion revenue target for 2025, factoring in new product launches and market stabilization [46]

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $991.55 million, representing a surprise of +0.27%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.43. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...